![]() Woodman currently serves as Chief Clinical Officer (CCLO) of Eisai’s Oncology Business Group where he is responsible for overseeing the development of the company’s next generation oncology products, including management of design protocols, implementation of clinical trials and interpretation of trial results in preparation for applications to global regulatory authorities. Woodman has already made significant contributions since joining Eisai almost one year ago and we are delighted to welcome him to our Board.”ĭr. ![]() Takashi Owa, Ph.D., Chairman and Chief Executive Officer of H3. His insights and guidance will be invaluable to the future growth of the company as we continue the research and development of our potential precision medicine treatments for patients with cancer,” said Dr. Woodman brings extensive industry and clinical knowledge to H3. “With over 18 years of oncology-focused pharmaceutical experience at both large and small biotechnology organizations and his years in academia, Dr. (H3), a U.S.-based precision medicine research & development subsidiary of Eisai Co., Ltd., today announced the addition of Richard Woodman, M.D. CAMBRIDGE, Mass.–(BUSINESS WIRE)– H3 Biomedicine Inc.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |